Series | number of patients | non-invasive IPMNa (n/%) | Invasive IPMNa (n/%) | Perioperative mortality (n/%) | Perioperative morbidity (Clavien Dindo/others; n(%)) | Survival | Recurrence rate | Comment |
---|---|---|---|---|---|---|---|---|
Salvia et al. [44] | n = 140 | 47 (34 %) | 83 (66 %) | 0 | 33 (24 %)(major complication) | 10-year overall survival non-invasive IPMNa 100 %; invasive IPMNa: 50 %. | n.s.b | |
Sohn et al. [14] | n = 136 | 84 (62 %) | 52 (38 %) | 5 (3.7 %) | 47 (35 %) | 5-year overall survival non-invasive IPMNa :77 %; invasive. IPMNa: 43 %. | n.s.b | |
D'Angelica et al. [15] | n = 62 a | 33a (52 %) | 30 (48 %) | 4 (6 %) | 31 (50 %) | 5-year-overall survival:75 %/10 year-overall survival:60 % | 23 % | a 1 patient Unresectable |
Rodriguez et al. [39] | n = 145 | 113 (78 %) | 32 (22 %) | 0 | 86 (59 %) | 10-year-overall survival: 70 %, invasive Carcinoma : 10-year-overall survival: 63 % | 6.9 % | only branch duct-IPMNa |
Niedergethmann [20] | n = 97 | 29 (30 %) | 68 (70 %) | 1 (1 %) | 55 (56.7 %) | median overall survival: 36 months | n.s.b | |
Sahora et al. [35] | n = 226 | 174 (77 %) | 52 (23 %) | 1.3 % | 34 % | n.s. | 8.5 % | only branch-duct-IPMNa |
Marchegiani et al. [21] | n = 173 | 48 (28 %) | 125 (72 %) | 0 | 15.6 % ("major surgical complications") | 10 year-overall survival: 69 % | 25 % | only main-duct-IPMNa |
present series | n = 54 | 24 (44 %) | 30 (56 %) | 2 (3.7 %) | 20 (37 %) | 5-year-overall survival non-invasive IPMNa: 100 %, invasive IPMNa 69 % | 6 (12 %) |